Yatiri Bio, Inc., a leader in proteomics-driven precision medicine, announces the successful acquisition of NGeneBioAI, Inc., a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition strengthens Yatiri Bio’s position at the forefront of biomarker discovery and translational drug development. The transaction includes the transfer of all NGeneBioAI assets, proprietary technologies, commercial agreements, and intellectual property in accordance with applicable agreements. As part of the deal, Yatiri Bio issued common stock to NGeneBio, the parent company of NGeneBioAI.
Read the full article: Yatiri Bio Acquires NGeneBioAI to Expand AI-Powered Proteomics Platform and Advance Precision Biomarker Discovery //
Source: https://www.globenewswire.com/news-release/2025/08/05/3127423/0/en/Yatiri-Bio-Acquires-NGeneBioAI-to-Expand-AI-Powered-Proteomics-Platform-and-Advance-Precision-Biomarker-Discovery.html